三年在线观看免费观看,日本成本人片不卡无码免费,成品人和精品人的区别三叶草,欧美国产日韩a在线视频y

Your location:Home > Newsroom > Industry News

Growth therapy boosts bypass patients


The therapy could help patients unsuitable for a bypass operation 

 

A therapy that promotes blood vessel growth could help heart patients unsuitable for bypass surgery, according to American research.

In a study of 24 patients unable to undergo a full heart bypass, 'growth factor' therapy improved blood flow in the heart without any adverse side effects.

In bypass surgery, veins or arteries from another part of the body are grafted alongside blocked blood vessels in the heart to improve blood flow.

But when patients have widespread heart disease, or their affected artery is very small a bypass is often unable to restore the blood flow.

The researchers inserted 10 capsules of the growth factor alongside the blocked artery.

 

Pain free

The research team found that patients who received the highest dose of the growth factor showed an improvement in blood supply and heart function, while those those given much lower doses or none at all did not improve.

All the patients who received the highest dosage were free of chest pain - angina - indicating that blood flow had been fully restored.

The researchers at the Angiogenesis Research Centre, Beth Israel Deaconess Medical Centre, Boston, are now conducting a larger study involving 120 patients.

The British Heart Foundation has welcomed the growth therapy research, but does not expect the technique to become clinical practice for several years.

 

'Blunt instrument'

A spokesman said it was too early to say whether the procedure would save lives.

"Although bypass surgery is now relatively routine, it's still a blunt instrument as you are transplanting a blood vessel to somewhere it's not supposed to be. Whereas promoting blood vessel growth is more in tune with the way the body is functioning already," he said.

Ten percent of bypasses become blocked within the first year and between five and 10% need further surgery, he added.

"But large-scale trials are needed to conclusively prove the procedure has lasting benefits, as well as ensuring there are no long-term safety issues.

"For example, if the technique promotes new blood vessel growth in the back of your eyes you could lose your sight."

About AVE   |   Newsroom   |   Products   |   Service   |   Contact Us
◎China. Changsha. AVE Science & Technology Co.Ltd. All Rights Reserved
<label id="pmmrb"></label>

<ul id="pmmrb"></ul>

    主站蜘蛛池模板: 龙州县| 清远市| 灵宝市| 宣汉县| 抚顺县| 繁昌县| 东乡族自治县| 西藏| 华容县| 平阴县| 新郑市| 张家川| 绍兴市| 林州市| 天水市| 陆河县| 邛崃市| 岐山县| 长子县| 松江区| 通江县| 荃湾区| 兴安盟| 抚州市| 瑞金市| 南澳县| 许昌县| 略阳县| 张家港市| 梁河县| 平舆县| 甘洛县| 酉阳| 文成县| 新乡市| 阿瓦提县| 沈丘县| 二连浩特市| 珠海市| 乌拉特中旗| 交城县|